42

DAFTAR PUSTAKA

Adam TCM, Westerperp MSP. 2005. Glucagon-like peptide release and satiety
after a nutrient challenge in normal-weight and obese subjects. British Journal of
Nutrition, 93: 845-851.

Ahren, B. 1998. Glucagon-like peptide 1 (GLP1): a gut hormone of potential

interest in the treatment of diabetes. Bio Essay, 20: 642-512.

Anini, Y., Brubaker, P.L. 2003. Muscarinic receptors control glucagon-like

peptide-1 secretion by human endocrine L cells. Endocrinology, 144:3244-3250.

Bello, N.T. and Moran, T.H., 2008. GLP1 Agonists and Satiety. Immun., Endoc.
& Metab. Agents in Med. Chem. 8(410),pp.3703-3709.

Campbell, J.E., Drucker, D.J. 2013. Pharmacology, physiology, and mechanism

of incretin hormone action. Cell Metabolism,17:1-19.

Chalasani N, Yomossi Z, Lavine J, Diehl A, Brunt E, Cusi K, Charlton M, Sanyal

A. 2012. The Diagnostic and Management of Non-Alcoholic Fatty Liver Disease
: Practice Guideline by the American Association for the Study of Liver Disease,
American College of Gastroenterology, and the American Gastroenterological
Association. Journal Hepatology 55(6): 2005-2023.

De Heer, J., Rasmussen, C., Coy, D.H., Holst, J.J. 2008. Glucagon –like peptide-
1 but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion
via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia,
51:2263-2270.

De Marinis, Y.Z. Salehi, A., Ward, C.E., Zhang, Q., Abdulkader, F., Bengstsson,
M., et al. 2010. GLP1 inhibits and adrenaline stimulates glucagon release by
differential modulation of N- and L-type Ca2+ channel-dependent exocytosis.
Cell Metab, 11:543-553.

Donath, M.Y., Burcelin, R. 2013. GLP1 effects on islets: hormonal, neuronal, or

paracrine? Diab. Care, 36(Suppl. 2): 145-148.

Donnely, D. 2012. The structure and function of the glucagon-like-peptide-1

receptor and its ligands. Br. J. Pharmacol, 166(1):27-41.

De Leon, D.D., Crutchlow, M.F., Ham, J.Y., Stoffers, D.A. 2006. Role of
glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus.
Int. J. Biochem. Cell Biology, 38(5-6): 845-59.

Drucker, DJ. 1998. Glucagon-Like Peptides; Perspectives in Diabetes

DIABETES. 47;159-65.
 43

Faerch K, Torekov S, Vistisen D, Johansen NB, Witte DR., Jonsson A, et al.

2015. GLP1 Response to Oral Glucose is Reduced in Prediabetes, Screen-
Detected Type 2 Diabetes, and Obesity and Influenced by Sex: THE
ADDITION-PRO Study. DIABETES. 64;2513-25.

Ferrari, CK. 2008. Metabolic Syndrome and Obesity: Epidemiology and

Prevention in Physical Activity and Exercise. J Exerc Sci Fit;6(2):87-96.

Gagnon, J., Baggio L.L., Drucker, D.J., Brubake, P.L. 2014. Ghrelin is a novel
regulator of glucagon-like peptide-1 secretion. Diabetes, 14:1-32.

Gariballa, S., Forster, F., Walters, S., Powers, H. 2006. A randomized, doble-
blind, placebo trial of nutritional supplementation during acute illness. Am. J.
Med.; 119: 693-699.

Goodman, NF, Cobin RH, Futterweitt W, Glueck JS, Legro RS, Carmina E.
Guide To Best Practices in The Evaluation and Treatment of Polycystic Ovary
Syndrome-Part 1. PCOS Best Practices, Endocr Pract. 2015;21(11): 1291-300.

Gutzwiller, J.P., Tschopp, S., Bock, A., Zehnder, C.E., Huber, A.R.,
Kreyenbuehl, M., et al. 2004. Glucagon-like peptide 1 induces natriuresis in
healthy subjects and insulin-resistant obese men. J Clin Endocrinol Metab,
89(6):3055-3061.

Holst, JJ. The Physiology of glucagon-like peptide-1. Physiol Rev 2007; 87:1409-
1439.

Idorn, T., Knop, F.K., Jorgensen, M.B., Christensen, M., Holst, J.J., Hornum,
M.,et al, 2014. Elimination and degradation of glucagon-like peptide-1 and
glucose-dependent insulinotropic polypeptide in patients with end-stage renal
disease. J Clin Endocrinol Metab, 10: 2013-2019.

Kahles, F., Meyer, C., Mollman, J., Diebold, S., Findiesen, H.M., Lebherz, C., et
al. 2014. GLP1 secretion is increased by inflammatory stimuli in an IL-6
dependent manner, leading to hyperinsulinemia and blood glucose lowering.
Diabetes, 63: 3221-9.

Kim, Y.O., Schuppan, D. 2012. When GLP1 hits the liver: a novel approach for
insulin resistance and NASH. Am. J. Physiol. Gastrointest. Liver Physiol,
302:759-761.

Lastya, A., Saraswati M.R., Suastika K. 2014. The low level of glucagon-like
peptide-1(GLP1) is a risk factor of type 2 diabetes mellitus. BMC Research
Notes. 7(849):1-4.

Lim, G.E., Brubaker, P.l. 2006. Glucagon like peptide-1 secretion by the L-cell.
Diabetes, 55(Suppl. 1):70-77.
 44

Little, T.J., Pilichiewicz, A.N., Russo, A., Philips, L., Jones, K.L., Nauck, M.A.,
et al. 2006. Effects of intravenous glucagon-like peptide-1 on gastric emptying
and intragastric distribution in healthy subjects: relationship with postprandial
glycemic and insulinemic responses. J Clin Endocrinol Metab, 91(5): 1916-
1923.

Madiyono. 2011. Perkiraan Besar Sampel. In: Sastroastmoro, S& Ismael, S.

Dasar-dasar Metodelogi Penelitian Klinis, Edisi 4. Jakarta,.Bab 17:348-382.

Manell H., Staaf J., Manukyan L., Kristinsson., Cen J., Stenlid R., et al. 2016.
Altered Plasma Levels of Glucagon, GLP-1 and Glicentin During OGTT in
Adolescents With Obesity and Type 2 Diabetes. J Clin Endocrinol Metab, 21(1):
1-9.

Munoz, JSG, Rodriguez DJ, Morante JJH. 2015. Diurnal rhytms of plasma GLP1
levels in normal and overweight/obese subjects: lack of effect of weight loss. J
Physiol Biochem.71:17-28.

Nauck, M.A., Vardarli I., Daecon, C.F., Holst, J.J. 2011. Secretion of glucagon-
like peptide-1 in type 2 diabetes: what is up, what is down?. Diabetologia.: 54:
10-18.

Pande Dwipayana, M, Saraswati, IMR, Gotera, W., Budhiartha, AAG., Suatika,

K, Sutanegara, Gunadi, IGN, Bajra Nadha, K., Rina, K., Wita., W., Santoso, A.,
Kajiwara., N., Taniguchi, M. 2011. Prevalensi Sindrom Metabolik pada Populasi
Penduduk Bali Indonesia. J Peny Dalam.12:1-4.

Ranganath, L.R., Beety, J.M., Morgan, L.M., Wright, J.W., Howland, R., Marks,
V.. 1996. Attenuated GLP1 secretion in obesity: cause or consequence?
Gut.38:916-9.

Raylene, A.R., Dorimont, C., gremlich, S., Nicholas-Metral, V., Ruegg, T. 2001.
A Human Cellular Model for Studying the Regulation of Glucagon-Like Peptide-
1 Secretion. Endocrinology.142(10):4522–28.

Robbins, S., Cotran, R. 2005. Pathologic Basis of Disease. 7th Edition. Elsevier
Saunders. Chapter 2 Acute Inflammation p.65-7.

Riset Kesehatan Dasar. 2010. Badan Penelitian dan Pengembangan Kesehatan.

Kementrian Kesehatan Republik Indonesia.

Saraiva, F.K., Sposito, A.C. 2014. Cardiovascular effects of glucagon-like

peptide 1 (GLP1) receptor agonists. Diabetology, 13(142):1-11.
 45

Steinert RE., Bisset CF., Asarian L., Horowitz M., Beglinger C., Geary N. 2016.
Ghrelin, CCK, GLP1, and PYY(3-36): Secretory Controls and Physiological
Roles in Eating and Glycemia in Health, Obesity, and After RGYB. Physiol Rev,
97(1): 411-463.

Tolhurst, G., Reinmann, F., Gribble, F.M. 2009. Nutritional regulation of

glucagon-like peptide-1 secretion. J Physiol, 587(1):27-32.

Ussher, J.R., Drucker, D.J. 2012. Cardiovascular biology of the incretin system.
Endocrine Rev, 33(2):1-28.

Vilsboll et al. 2001. Reduced Postprandial Concentrations of Intact Biologically

Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients. Diabetes.50:1-6.

Wang X.C., Liu H., Chen J., Li Y., Qu S. 2015. Multiple Factors Related to The
Secretion of Glucagon-Like Peptide 1. Int J of Endorin, pp: 1-11.

WHO. 2014. Metabolic Syndrome. (cited 2017 June. 29). Available from: URL:
http://www.who.int/mediacentre/factsheet/fs211/en/.

WHO. 2017. Global Health Observatory (GHO) data. (cited 2017 July 15).
Available from: URL: http://www.who.int/gho/ncd/risk_factors/obesity_text/en/.